Alirocumab
is a fully human monoclonal antibody (IgG1) targeting proprotein convertase
subtilisin/kexin type 9 (PCSK9). It is developed as an adjunct to diet and
maximally tolerated statin therapy for the treatment of adults with
hyperlipidaemia, including hypercholesterolaemia and heterozygous familial
hypercholesterolaemia (HeFH) [1, 2].
Alirocumab
is a human monoclonal antibody of the IgG1 isotype. Chemically, it is made of
two disulfide-linked human heavy chains, each disulfide-linked to a human light
chain. It has an approximate molecular weight of 146 kDa. It is produced using
Chinese hamster ovary cells transfected with recombinant DNA.
